Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort

被引：0
|
作者：
Kallweit, U. [1 ]
Jelcic, I. [1 ]
Braun, N. [1 ]
Fischer, H. [1 ]
Zoerner, B. [1 ]
Schreiner, B. [1 ]
Sokolov, A. [1 ]
Martin, R. [1 ]
Weller, M. [1 ]
Linnebank, M. [1 ]
机构：
[1] Univ Zurich Hosp, CH-8091 Zurich, Switzerland
来源：
MULTIPLE SCLEROSIS JOURNAL | 2011年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P950
引用
收藏
页码：S429 / S429
页数：1
相关论文
共 50 条
  • [41] Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England
    Hettle, Robert
    Harty, Gerard
    Wong, Schiffon L.
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (07) : 676 - 686
  • [42] Cognitive dysfunction in relapsing-remitting multiple sclerosis: Relation to quality of life and longitudinal changes under treatment with natalizumab
    Krause, I.
    Kern, S.
    Schultheiss, T.
    Horntrich, A.
    Hanso, H.
    Thomas, K.
    Ziemssen, T.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (05) : S46 - S46
  • [43] Natalizumab Reduces Clinical and MRI Disease Activity in Second Line Treatment of Relapsing-Remitting Multiple Sclerosis: Results of a Multicenter Study
    Putzki, Norman
    Yaldizli, Oezguer
    Maeurer, Mathias
    Kuckert, Sabine
    Cursiefen, Simone
    Tettenborn, Barbara
    Limmroth, Volker
    NEUROLOGY, 2009, 72 (11) : A236 - A236
  • [44] Experiences in treatment of multiple sclerosis with natalizumab from a real-life cohort over 15 years
    Auer, Michael
    Zinganell, Anne
    Hegen, Harald
    Bsteh, Gabriel
    Di Pauli, Franziska
    Berek, Klaus
    Fava, Elena
    Wurth, Sebastian
    Berger, Thomas
    Deisenhammer, Florian
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [45] Treatment of multiple sclerosis with natalizumab: experiences from a real-life cohort over 15 years
    Auer, M.
    Zinganell, A.
    Hegen, H.
    Bsteh, G.
    Di Pauli, F.
    Berek, K.
    Fava, E.
    Wurth, S.
    Berger, T.
    Deisenhammer, F.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 588 - 588
  • [46] Experiences in treatment of multiple sclerosis with natalizumab from a real-life cohort over 15 years
    Michael Auer
    Anne Zinganell
    Harald Hegen
    Gabriel Bsteh
    Franziska Di Pauli
    Klaus Berek
    Elena Fava
    Sebastian Wurth
    Thomas Berger
    Florian Deisenhammer
    Scientific Reports, 11
  • [47] The real-world efficacy of natalizumab and fingolimod in relapsing-remitting multiple sclerosis. An observational, multicentre Italian study
    Curti, E.
    Tsantes, E.
    Baldi, E.
    Caniatti, L.
    Ferraro, D.
    Sola, P.
    Granella, F.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 611 - 612
  • [48] Characteristics of real-world disability improvement in relapsing-remitting multiple sclerosis patients treated with natalizumab in the TYSABRI® Observational Program
    Wiendl, H.
    Butzkueven, H.
    Kappos, L.
    Spelman, T.
    Trojano, M.
    Dong, Q.
    Campbell, N.
    Ho, P. -R.
    Licata, S.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 373 - 373
  • [49] Effects of natalizumab treatment on sustained improvement in physical disability and quality of life in patients with relapsing multiple sclerosis
    Munschauer, F.
    Giovannoni, G.
    O'Connor, P. W.
    Phillips, J. T.
    Polman, C. H.
    Pace, A.
    Kim, R.
    Hyde, R.
    Panzara, M. A.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 285 : S109 - S109
  • [50] Effect of Natalizumab on Clinical and Radiological Disease Activity in a French Cohort of Relapsing Remitting Multiple Sclerosis Patients
    Melin, Annick
    Outteryck, Olivier
    Ongagna, Jean-Claude
    Fleury, Marie
    Zephir, Helene
    Lacour, Arnaud
    Berteloot, Anne-Sophie
    Blanc, Frederic
    Vermersch, Patrick
    De Seze, Jerome
    NEUROLOGY, 2011, 76 (09) : A71 - A71
12345